Arena Pharmaceuticals Upgraded To Outperform From Market Perform At Wells Fargo

Image result


Wells Fargo analyst Jim Birchenough upgraded Arena Pharmaceuticals (ARNA) to Outperform and raised his price target for the shares to $53 from $19. The stock closed yesterday up 7% to $36.21.

An improved FDA environment could facilitate approval of ralinepag in pulmonary arterial hypertension, Birchenough tells investors in a research note. He's upgrading the shares ahead of the Phase 2 data for S1P modulator etrasimod in ulcerative colitis.

The analyst believes recent data from Celgene's (CELG) competing S1P modulator ozanimod "lowers the bar for differentiation." Both of Arena's assets "could attract large Pharma interest," Birchenough adds.

Disclaimer:, Inc.'s staff does NOT provide any individual investment advice or money management assistance., Inc.'s employees are not brokers, dealers or registered ...

How did you like this article? Let us know so we can better customize your reading experience. Users' ratings are only visible to themselves.


Leave a comment to automatically be entered into our contest to win a free Echo Show.